Subject: (Copy) NIH GUIDE - Vol. 19, No. 19, May 18, 1990
From: Dot Baker <[email-masked]>
To: [email-masked]
Date: Thu, 17 May 90 08:09 EST

Hello Again,
     This is the NIH Guide for May l8, l990.  Please post to the
NIH Listserver as:
    NIHGUIDE.051890
  Thanks.
         Dottie
 ---------------------------- Text of forwarded message -----------------------
     
X-comment: NIH Guide (including TOC) contained 14 pages (1120 lines)
X-comment: RFAs described:  DK-90-11, AI-90-07

     

     
NIH GUIDE - Vol. 19, No. 19, May 18, 1990

                                   NOTICES

RETENTION OF INTEREST EARNED ON ADVANCES OF GRANT FUNDS .....(84/96)......... 1
Public Health Service
Index:  PUBLIC HEALTH SERVICE

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

OFFICE OF CANCER COMMUNICATIONS COMMUNITY SUPPORT CONTRACT (RFP) ............ 1
National Cancer Institute                                    (102/126)
Index:  CANCER

DIABETES CENTERS (RFA DK-90-11) .............................(129/249)....... 1
National Institute of Diabetes and Digestive and Kidney Diseases
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

COOPERATIVE CLINICAL TRIALS IN TRANSPLANTATION (RFA AI-90-07) ............... 3
National Institute of Allergy and Infectious Diseases   (252/329, 1124/1892)
Index:  ALLERGY, INFECTIOUS DISEASES

                        ONGOING PROGRAM ANNOUNCEMENTS

BEHAVIORAL CONSEQUENCES OF LONG-TERM USE OF ABUSED DRUGS (PA-90-10) ......... 4
National Institute on Drug Abuse                        (335/533)
Index:  DRUG ABUSE

DOMESTIC ANIMAL MODELS OF RETROVIRAL ASSOCIATED MALIGNANCIES (PA-90-11) ..... 6
National Cancer Institute                               (536/689)
Index:  CANCER

OBESITY, ENDOCRINE AND FAT METABOLISM AND CANCER RISK (PA-90-12) ............ 8
National Cancer Institute                               (692/909)
Index:  CANCER

MINORITY INSTITUTIONAL RESEARCH TRAINING PROGRAM (PA-90-13) .................11
National Heart, Lung, and Blood Institute           (912/975, 1895/2171)
Index:  HEART, LUNG, BLOOD

MINORITY SCHOOL FACULTY DEVELOPMENT AWARD (PA-90-14) ..(978/1033, 2174/2494).12
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD

                                   ERRATUM

ACADEMIC AWARD IN SYSTEMIC AND PULMONARY VASCULAR DISEASE ..(1044/1084)......13
National Heart, Lung, and Blood Institute
Index:  HEART, LUNG, BLOOD

THE STUDY OF THE ETIOLOGY AND PATHOGENESIS OF INFLAMMATORY BOWEL
DISEASE (PA-90-05) .........................................(1087/1099)......13
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Allergy and Infectious Diseases
Index:  DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES, ALLERGY,
        INFECTIOUS DISEASES

     
                                   NOTICES

RETENTION OF INTEREST EARNED ON ADVANCES OF GRANT FUNDS
     
P.T. 34; K.W. 1014006
     
Public Health Service
     
This is a reminder that the amount of interest earned on advances of grant
funds which may be retained by nongovernmental grantees for administrative
expenses of $100.  The Notice of Proposed Rulemaking (NPRM) published in the
FEDERAL REGISTER on November 4, 1988 to amend OMB Circular A-110 proposed to
raise the amount to $250.  However, the NPRM has NOT been finalized.
Therefore, the $100 limit specified in Section 74.92 of 45 CFR Part 74 is
still in effect.

                   NOTICES OF AVAILABILITY (RFPs AND RFAs)

OFFICE OF CANCER COMMUNICATIONS COMMUNITY SUPPORT CONTRACT
     
MASTER AGREEMENT RFP AVAILABLE:  NCI-CO-03891-63
     
P.T. 16; K.W. 0403004
     
National Cancer Institute
     
The National Cancer Institute, Prevention and Control Contracts Section, is
soliciting proposals for a Master Agreement on projects to support the
planning, development and implementation of public information projects which
require application at the regional or local level.  The Request for Proposals
(RFP) will be issued approximately 15 days after publication of this
announcement and the closing date will be approximately 45 days after
issuance.
     
Copies of the RFP may be available by sending a written request to:
     
Ms. Tina Huyck
Research Contracts Branch
9000 Rockville Pike
Executive Plaza South, Suite 635
National Cancer Institute
Bethesda, MD  20892
Telephone:  (301) 496-8628

DIABETES CENTERS
     
RFA AVAILABLE:  DK-90-11
     
P.T. 04; K.W. 0715075, 0715135, 0785050, 0710030
     
National Institute of Diabetes and Digestive and Kidney Diseases
     
Application Receipt Date:  November 12, 1990
     
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
invites applications for funding of up to two Diabetes and Endocrinology
Research Center (DERC) grants to be competitively awarded in Fiscal Year 1992.
     
BACKGROUND
     
DERCs are part of an integrated program of diabetes-related research support
provided by NIDDK.  These centers have provided a focus for increasing
collaboration and cost effectiveness among groups of successful investigators
at institutions with established comprehensive diabetes research bases.
     
OBJECTIVES AND SCOPE
     
The objectives of the DERCs are to bring together clinical and basic science
investigators from relevant disciplines in a manner which will enhance and
extend the effectiveness of research related to diabetes and its
complications.  A diabetes center must be an identifiable unit within a single
university medical center or a consortium of cooperating institutions,
including an affiliated university.  An existing program of excellence in
biomedical research in the area of diabetes and related metabolic and
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 1
endocrine disorders is required.  This research should be in the form of
NIH-funded research projects, program projects or other peer-reviewed research
that is in existence at the time of submission of a center application.  Close
cooperation, communication, and collaboration among all involved personnel of
all professional disciplines are ultimate objectives.  Applicants should
consult with NIDDK staff concerning plans for the development of the center.
     
The DERCs are based on the core concept.  Cores are defined as shared
resources that enhance productivity or in other ways benefit a group of
investigators working in diabetes or diabetes-related areas to accomplish the
stated goals of the center.  Two other types of activities may also be
supported with center funding--a pilot and feasibility program and an
enrichment program.  The pilot and feasibility program provides modest support
for new initiatives or feasibility research studies.  This program is directed
at new investigators or established investigators in other research
disciplines where their expertise may be applied to diabetes research.  The
center grant may also include limited funds for program enrichment such as
seminars, visiting scientists, consultants, workshops, etc.
     
MECHANISM OF SUPPORT
     
NIDDK expects to award up to two DERC grants in Fiscal Year 1992 on a
competitive basis.  The receipt of two competing continuation applications is
anticipated, which will compete with other applications received in response
to this announcement.  Foreign institutions are not eligible to apply.  The
anticipated awards will be for five years and will be contingent upon the
availability of appropriated funds.  Requests for support must be limited to
no more than $750,000 in direct costs per year.  The Request for Applications
(RFA) (general description and Guidelines for the DERC) and consultation may
be obtained from:
     
Dr. Sanford A. Garfield
Diabetes Centers Program Director
Division of Diabetes, Endocrinology, and Metabolic Diseases
Westwood Building, Room 626
National Institute of Diabetes and Digestive and Kidney Diseases
Bethesda, MD  20892
Telephone:  (301) 496-7418
     
REVIEW PROCEDURES
     
Applications for a DERC grant will be evaluated in national competition by the
NIH grant peer review process.  Applications will be reviewed initially by a
special review committee convened by the NIDDK and subsequently by the
National Diabetes and Digestive and Kidney Diseases Advisory Council.
     
METHOD OF APPLYING
     
Potential applicants are urged to submit a letter of intent regarding their
application.  The letter of intent is nonbinding and is not a precondition for
an award.  The letter of intent should include the name(s) of the principal
investigator and principal collaborators, descriptive titles of the core
facilities and pilot/feasibility projects, and the organization(s) involved.
Letters of intent should be sent to:
     
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Westwood Building, Room 406
Bethesda, MD  20892
     
Applications must be submitted using PHS Form 398 (Rev.  10/88).  The RFA
label contained in the application kit must be affixed to the bottom of the
face page of the original copy of the application.  Failure to use this label
could result in delayed processing and review of your application.  Complete
line 2 of the application face page by inserting "Diabetes Centers, RFA
DK-90-11."
     
Mail the completed application (original and four copies) to:
     
Application Receipt Office
Division of Research Grants
Westwood Building, Room 240
National Institutes of Health
Bethesda, MD  20892**

     
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 2
Simultaneously submit two copies to:
     
Chief, Review Branch
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 406
Bethesda, MD  20892
     
The special single receipt date for submissions in response to this
announcement is November 12, 1990, with earliest funding December 1, 1991.

COOPERATIVE CLINICAL TRIALS IN TRANSPLANTATION
     
RFA AVAILABLE:  AI-90-07
     
P.T. 34; K.W. 0745065, 0755015, 0745045, 0745040
     
National Institute of Allergy and Infectious Diseases
     
Letter of Intent Receipt Date:   August 17, 1990
Application Receipt Date:  October 12, 1990
     
The National Institute of Allergy and Infectious Diseases (NIAID) through the
Genetics and Transplantation Branch (GTB) of the Division of Allergy,
Immunology, and Transplantation (DAIT) invites applications from investigators
desiring to participate under Cooperative Agreements in a multi-center
cooperative clinical trial.  The goal of this study is to evaluate new and
currently used immunotherapeutic protocols in the treatment and prevention of
acute kidney graft rejection.
     
In order to meet the stated objectives effectively, a network of centers will
be established to conduct clinical trials using common protocols thus
facilitating the study of large numbers of patients in a shorter time-frame
than possible were individual centers to act alone.
     
The information acquired through this cooperative clinical trial will benefit
the public by improving the prognosis of patients on dialysis waiting for a
kidney transplant, by expediting the process of evaluating new
immunosuppressive therapeutic regimens and by speeding the transfer of basic
knowledge to clinical application.
     
The NIH places special emphasis on the need for inclusion of minorities and
women in studies of diseases which disproportionately affect them and also
urges that applicants give added attention, where feasible and appropriate, to
their inclusion in other clinical studies.  For proposed population-based
studies which include neither women nor minorities, a clear rationale for not
including them must be provided.  In attempting to include either group in a
particular study, attention must be paid to such issues as research design and
sample size.
     
Successful applicant(s) funded under this Request for Applications (RFA) will
be supported through Cooperative Agreements.  Cooperative Agreements are
awarded to both not-for-profit and for-profit organizations and institutions.
This type of solicitation is utilized when it is desired to encourage
investigator-initiated research projects in areas of special importance to the
NIH and where substantial programmatic involvement by staff is anticipated.
This RFA solicitation represents a single competition with a specified
deadline for receipt of applications.  There are no present plans to reissue
this RFA at any future time.  The NIAID may invite competitive continuation
applications upon expiration of the initial funding period contingent on the
continued availability of funds for this purpose and the continued need to
conduct clinical trials in this area.  All applications received in response
to the RFA will be reviewed by an Initial Review Group convened by the
Division of Extramural Activities, NIAID, and by the National Advisory Allergy
and Infectious Diseases Council.
     
The deadline for the receipt of applications in response to this RFA is
October 12, 1990.  Applications should be prepared and submitted in accordance
with the aims and requirements set forth in the remainder of this document.
     
NIAID has set aside $2 million total costs for funding the initial year.
     
For a copy of this RFA, please contact:

     

     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 3
Stephen M. Rose, Ph.D.
Chief, Genetics and Transplantation Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 754
5333 Westbard Ave.
Bethesda, MD  20892
Telephone :  (301) 496-5598
FAX Number:  (301) 402-0175

                        ONGOING PROGRAM ANNOUNCEMENTS

BEHAVIORAL CONSEQUENCES OF LONG-TERM USE OF ABUSED DRUGS
     
PA:  PA-90-10
     
P.T. 34; K.W. 0404009, 0404000, 0710085
     
National Institute on Drug Abuse
     
PURPOSE
     
The purpose of this program announcement is to encourage the submission of
research proposals describing the investigation of any persistent, residual
behavioral effects of abused drugs in human or animal subjects following
long-term use.  The studies should be directed at evaluating possible changes
in behavior following withdrawal.  In all cases, the subjects must be drug
abstinent prior to the time of evaluation.
     
This announcement is intended to stimulate the study for the possible presence
of residual effects of any major drug of abuse such as cocaine, phencyclidine,
methamphetamine or marijuana, used alone or in combination with each other or
with alcohol.  Applicants interested in the specific effects of alcohol on
behavior are referred to the National Institute on Alcohol Abuse and
Alcoholism announcement "Alcohol Research Grants" revised January 1990.
     
RESEARCH OBJECTIVES
     
After many months or years of drug taking, some individuals eventually seek
treatment and subsequently no longer abuse drugs.  Basic and clinical studies
are needed to describe behavioral deficits which may persist after prolonged
drug abuse.
     
More research is needed to address questions such as:  l) Which drugs and drug
combinations have lasting behavioral-neurotoxic effects?  2) Is there a
particular age where use of drugs may possibly be more deleterious to
subsequent impairment in performance or psychosocial status?  3) If subtle
behavioral deficits or electrophysiological changes exist in abstinent drug
abusers, do they have clinical significance?  4) To what extent can individual
differences in cognitive performance be described and explained in populations
of abstinent drug abusers?  5) Is there a relationship between number of
previous drug withdrawal episodes and subsequent memory/cognitive performance?
     
Research studies are solicited that evaluate and/or systematically track the
degree of performance and learning impairment and possible brain dysfunction
present after long-term drug abuse.  Since some neurophysiological performance
deficits in either adults or children may have been present prior to the use
of drugs, innovative ways are needed to access this information, e.g., through
past tests or school reports.  Skills that could be studied include, but are
not limited to, motor dexterity, sensory processing, attention, reaction time,
language functioning, verbal reasoning, visuospatial analysis, memory, degree
of abstraction, planning and problem solving as well as adaptative behavior.
A special need exists for the development of computer systems to assist in the
evaluation for possible residual drug effects on performance.
     
Physiological measurements, such as electroencephalogram, evoked potentials,
autonomic or motoric measures, may be included if they can be directly related
to the performance measure being studied and thus provide additional
information regarding residual drug effects.  Other measures such as brain
scanning or neuroendocrine procedures may be included but only when the major
emphasis is on relating these variables to impairments in behavior.
     
Clinical diagnostic assessments for psychopathology or scholastic abilities
may be included to more completely evaluate performance deficits in long-term
drug abusers.

              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 4
Populations studied can include any age, sex or culture, but there is a
special need to clinically evaluate children, adolescents and the elderly as
well as groups with physical or mental handicapping conditions and minorities.
     
Proposals for animal models (adult or developmental) describing any residual
effect of abused drugs on behavior may be submitted.  Drugs may be
administered by the experimenter or self-administered by the animal.
Behavioral measures, such as operant conditioning, other learning or memory
tasks, social dominance, aggression, sexual activity, or motoric behavior, may
be used.  Correlative biological measures, such as neurophysiological, or
neurochemical, may be used if they can be directly related to behavioral
performance.
     
MECHANISM OF SUPPORT
     
Support mechanisms include:  (l) Research Projects (R01), (2) Small Grants
(R03), (3) First Independent Research Support and Transition Awards (R29).
     
INCLUSION OF MINORITIES AND WOMEN IN STUDY POPULATIONS
     
Applicants are urged to give added attention (where feasible and appropriate)
to the inclusion of minorities in study populations for research into the
etiology of diseases, research in behavioral and social sciences, clinical
studies of treatment and treatment outcomes, research on the dynamics of
health care and its impact on disease, and appropriate interventions for
disease prevention and health promotion.  If minorities are not included in a
given study, a clear rationale for their exclusion should be provided.
     
Applicants are urged to consider the inclusion of women in the study
populations for all clinical research efforts.  Exceptions would be studies of
diseases which exclusively affect males or where involvement of pregnant women
may expose the fetus to undue risks.  Gender differences should be noted and
evaluated.  If women are not to be included, a clear rationale should be
provided for their exclusion.
     
In order to provide more precise information to the treatment community, it is
recommended that publications resulting from research supported by the
Alcohol, Drug Abuse, and Mental Health Administration in which the study
population was limited to one sex for any reason other than that the disease
or condition studied exclusively affects that sex, should state, in the
abstract summary, the gender of the population studied, e.g., "male patients,"
"male volunteers," "female patients," "female volunteers."
     
ELIGIBILITY
     
Applications may be submitted by public or private nonprofit or for-profit
organizations such as universities, colleges, hospitals, laboratories, units
of State or local governments, and eligible agencies of the Federal
governments.  Women and minority investigators are encouraged to apply.
Applications are especially encouraged from State governments with research
units and/or State governments collaborating with university-based research
units.
     
APPLICATION PROCEDURES
     
Application kits (PHS 398, rev.  10/88) containing the necessary forms and
instructions may be obtained from business offices or offices of sponsored
research at most universities, colleges, medical schools, and other major
research facilities.  If such a source is not available, the following office
may be contacted for the necessary application material:  Grants Management
Branch, National Institute on Drug Abuse, Room 8A-54, 5600 Fishers Lane,
Rockville, MD 20852, Telephone:  (301) 443-6720.
     
The signed original and six (6) copies of the completed application should be
sent to:
     
Division of Research Grants, NIH
Westwood Building, Room 240
Bethesda, MD  20892**
     
RECEIPT AND REVIEW SCHEDULE:
     
The Division of Research Grants, NIH, serves as a central point for receipt of
applications for most discretionary PHS grant programs.  Applications received
under this announcement will be assigned to an Initial Review Group (IRG) in
accordance with established Public Health Service referral guidelines.  The
review group, consisting primarily of non-Federal scientific and technical
experts, will review the applications for scientific and technical merit.
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 5
Notification of the review recommendations will be sent to the applicant after
the initial review.  Applications will receive a second-level review by an
appropriate national advisory council whose review may be based on policy as
well as scientific merit consideration.  Only applications recommended for
approval by the Council may be considered for funding.
     
Applications submitted in response to this announcement are not subject to the
intergovernmental review requirements of Executive Order 12372, as implemented
through Department of Health and Human Service regulations at 45 CFR Part 100.
Applications received after the deadline for receipt of applications in a
given review cycle will be reviewed in the next appropriate review cycle
scheduled, as indicated below.
     
Receipt of          Initial           Advisory Council      Earliest
Applications        Review                 Review         Start Date
     
Feb/Mar l*         June/July             Sept/Oct          December 1
June 1/July 1*     Oct/Nov               Jan/Feb            April 1
Oct l/Nov 1*       February/March        May/June            July 1
     
* Competing continuation, supplemental and revised applications are to be
submitted on these dates.
     
REVIEW CRITERIA
     
Criteria for scientific/technical merit review of applications will include
the following:  significance and originality from a scientific or technical
standpoint of the goals of the proposed research; adequacy of the methodology
proposed to carry out the research; feasibility of the proposed research;
qualifications and research experience of the principal investigator and other
key personnel; availability of adequate facilities, other resources, and
collaborative arrangements necessary for the research; appropriateness of
budget estimates for the proposed research activities; and adequacy of
provisions for the protection of human or animal subjects, as applicable.
     
AWARD CRITERIA
     
Applications recommended for approval by the appropriate National Advisory
Council will be considered for funding on the basis of overall scientific,
clinical and technical merit of the proposal as determined by peer review,
appropriateness of budget estimates, program needs and balance, policy
consideration, adequacy of provisions for the protection of human or animal
subjects, and availability of funds.
     
INQUIRIES
     
Further information and consultation on requirements relevant to this program
announcement can be obtained from:
     
Dr. John Spencer
National Institute on Drug Abuse
5600 Fishers Lane, Roon 10A-46
Rockville, MD  20857

DOMESTIC ANIMAL MODELS OF RETROVIRAL ASSOCIATED MALIGNANCIES
     
PA:  PA-90-11
     
P.T. 34; K.W. 0755020, 1002045, 0715035, 0765033
     
National Cancer Institute
     
BACKGROUND
     
The National Cancer Institute (NCI) has played the major role in supporting
research on oncogenic viruses of domestic animals as models for human
malignancies.  The purpose of this Program Announcement is to inform the
scientific community of the NCI's continuing interest in supporting basic
research on retroviral pathogenesis and neoplastic sequelae in domestic animal
models of human cancer.  Studies of domestic animal retroviruses have the
potential to provide valuable basic information on the mechanism(s) of cancer
induction by viruses and to serve as models for the initial evaluation of
intervention strategies prior to human clinical trials.
     
Mammalian retroviruses have been isolated from humans, monkeys, mice, cats,
cows, goats, sheep, pigs and horses.  In some virally infected animals,
neoplastic and Kaposi's sarcoma-like lesions have been observed, supporting
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 6
the hypothesis that retroviruses may be directly or indirectly involved in the
development of malignancies and disease progression.  Retrovirus animal models
may therefore aid in investigations of the initiation and progression of
neoplasia of viral origin and provide a better understanding of the role of
viruses in the etiology of human cancer.
     
Progress in most of these domestic animal systems has been limited by an
indolent disease course and the fact that the neoplasms occur in a limited
percentage of animals.  Other limitations include:  the lack of reagents for
typing of cells of the immune system; probes for some viruses are either not
available or are not well characterized; monoclonal antibodies for some viral
antigens are not available.  Additionally, the number of scientists actively
conducting research on each virus is small.  One goal of this Program
Announcement is to encourage collaborations between scientists with
complementary areas of research expertise, such as molecular biology of
retroviruses and pathogenesis or immunology, with the intent of accelerating
progress in these important cancer models.  The overall purpose of the
proposed Program Announcement is to help stimulate research activity in these
virus cancer models and overcome these limitations.
     
It is anticipated that research on viruses of domestic animals will continue
to provide information which will aid in studies of retrovirus-associated
human malignancies and provide insights into the etiology, prevention and
treatment of human malignancies.
     
RESEARCH GOALS AND SCOPE
     
This Program Announcement reaffirms the NCI's continuing interest in the
support of basic research on retroviral pathogenesis in domestic animals as
models for human malignancies.  Such studies will aid in understanding the
properties of viruses and features of the host response that determine disease
progression from initial virus infection to neoplastic sequelae.  Retroviruses
appropriate for this Program Announcement include those of large domesticated
livestock, such as cows, horses, sheep, goats and pigs; specifically excluded
are retroviruses of cats, dogs, mice, primates and the avian species.
Collaborative efforts between scientists with complementary areas of research
expertise will be encouraged.  Specific research topics of interest to the NCI
include, but are not limited to:  1) studies emphasizing the development and
utilization of known retroviral domestic animal models for investigations of
disease pathogenesis from the initial infection to the development of
pre-neoplastic lesions and neoplastic sequelae; 2) studies emphasizing the use
of domestic animals for investigations of virus-host interactions to define
and understand viral pathogenic and immune function alterations leading to
pre-neoplastic lesions and neoplastic sequelae, including the role of other
RNA and DNA virus cofactors; 3) studies which emphasize the expression and
regulation of viral or cellular genes in pre-neoplastic lesions and malignant
tissues from retrovirus-infected domestic animals; 4) studies to isolate and
characterize new retroviruses from normal, pre-neoplastic lesions and
neoplastic tissues of domestic animals and study the mechanisms of oncogenesis
of these viruses.  Where appropriate, collaborative arrangements to facilitate
the achievement of research goals should be considered.
     
MECHANISM OF SUPPORT
     
This program will be supported through traditional research grants (R01).
Awards will be administered under Public Health Service grants policy as
stated in the PHS Grants Policy Statement, DHHS Publication Number (OASH)
82-50,000, revised January 1, 1987.  The total project period for applications
submitted in response to the Program Announcement should not exceed five
years.
     
Applications will compete for available funds with all other approved
applications assigned to the Institute.  The following will be considered
making funding decisions:  (a) quality of the proposed project as determined
by peer review; (b) availability of funds; (c) balance among research areas of
the program announcement.
     
ELIGIBILITY
     
Non-profit and for-profit organizations and institutions, governments and
their agencies, and individuals are eligible to apply.  Foreign and domestic
institutions are eligible.
     
APPLICATION, SUBMISSION AND REVIEW PROCEDURES
     
Applications should be submitted on Form PHS-398, revised 10/88, available in
the business or grants office at most academic or research institutions, or
from the Division of Research Grants, NIH.  Applications will be accepted in
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 7
accordance with the date for receipt of applications on or before October 1,
February l, or June 1.
     
Applications will be assigned on the basis of established Public Health
Service referral guidelines.  Applications will be reviewed for scientific and
technical merit by regular study sections of the NIH.  Following study section
review, the applications will receive a second-level review by the appropriate
national advisory council.
     
The phrase "IN RESPONSE TO PA-90-11 - DOMESTIC ANIMAL MODELS OF RETROVIRAL
ASSOCIATED MALIGNANCIES" should be typed on line 2 of the face page of the
application and check "YES" in the box.  Applications should be responsive to
the Program Announcement and the Abstract of the Research Plan should contain
a clear statement relating the proposed research to domestic animal viral
oncogenesis.
     
The original and six copies should be sent to:
     
Grant Applications Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**
     
Written or telephone inquiries concerning the objectives and scope of this
Program Announcement or inquiries about whether or not specific proposed
research would be responsive are encouraged and should be directed to Dr.
Kenneth J. Cremer at the address below.  The program director welcomes the
opportunity to clarify any issues or questions from potential applicants.
     
Dr. Kenneth J. Cremer
Program Director
AIDS Virus Studies
Biological Carcinogenesis Branch
Division of Cancer Etiology
National Cancer Institute
Executive Plaza North, Room 540
Bethesda, MD  20892
Telephone:  (301) 496-6085
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.393, Cancer Cause and Prevention Research.  Awards are under authorization
of the Public Health Service Act, Title III, Section 301(c), Public Law
78-410, as amended; 42 U.S.C. 241; the Small Business Innovation Development
Act, Public Law 97-219, and Section 410 as amended by Public Law 99-158, 42
U.S.C. 285; and administered under PHS grant policies and Federal Regulations
42 CFR 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.

OBESITY, ENDOCRINE AND FAT METABOLISM AND CANCER RISK
     
PA:  PA-90-12
     
P.T. 34; K.W. 0715145, 0715035, 0765025, 0411005, 0785050
     
National Cancer Institute
     
I.  INTRODUCTION
     
The Division of Cancer Etiology of the National Cancer Institute invites
regular research project (R01) grant applications from interested
investigators for epidemiologic studies to define the relationship between
obesity and cancer etiology.
     
II.  BACKGROUND
     
Obesity influences the risk of many diseases including certain types of
cancer.  In particular, risk of endometrial cancer at all ages is increased by
obesity.  Other sites for which obesity has been reported to increase cancer
risk are breast (at postmenopausal ages), gallbladder, kidney, prostate, ovary
and colon, although findings are not consistent among studies.  An inverse
association has been reported between body mass and the risk of premenopausal
breast cancer.
     
Risk of several diseases varies not only with degree of obesity but also with
the body distribution of fat.  This is true for hypertension, diabetes,
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 8
gallbladder disease and mortality due to all causes and also has been reported
for breast cancer.  An association between fat patterning and changes in
endocrine metabolism also has been reported in response to changing
environmental exposures.
     
Distribution of body fat varies with age, degree of obesity, race and
ethnicity, and is affected by the genetic background of the individual.  In
recent years, improved methods of measuring body fat distribution have become
available, and these methods have been used in evaluating the various indices
for estimating body fat mass or differences in its patterning.  For example,
recent data from Sweden support the use of weight/(height exp(0.58)) as an
estimator of total adipose tissue in preference to weight/(height exp(2)) or
weight/(height exp(1.5)); these latter ratios have been used extensively in
epidemiologic studies of the effects of obesity.  Procedurally, waist and hip
measures entered into multivariate analyses are superior to the use of the
waist/hip ratio as an analytic variable.  Although caloric intake and
expenditure are intimately related to obesity and to adipose tissue deposition
or mobilization, these factors have not been taken into consideration together
with adequate measures of fat distribution in studying the relationship of
cancer risk to obesity.
     
III RESEARCH GOALS AND SCOPE
     
The purpose of this announcement is to encourage further studies to clarify
associations recently found between body fat distribution and cancer risk, or
risk factors, as well as to extend knowledge through the investigation of
related or new hypotheses.  A major goal is the definition of differences in
adipose tissue metabolism and hormone metabolism from varied environmental
exposures as they relate to site-specific cancer risks.
     
Research topics of interest include but are not limited to:
     
  o  Development and validation of improved measurement techniques for
     cancer risk factors related to adiposity, caloric balance, steroid
     hormone and fat metabolism, and diet; assessment of interaction and
     its effect on specific cancer risks.
     
  o  The use of better measures of total adiposity and of the
     distribution of adipose tissue in evaluating risk of various cancer
     sites, such as breast, endometrium, prostate, colon, gallbladder,
     ovary, lung and kidney.  This includes interest in definition of
     cancer risk associated with the deposition or metabolic activity of
     adipose tissue in the visceral compartment, and clarification of
     any effect of height.
     
  o  The impact on site-specific cancer risk of age-, ethnic-, or
     race-related variation in adiposity or in adipose tissue
     distribution, taking into consideration relevant confounding
     factors.
     
  o  Evaluation of the relationship between site-specific cancer risk
     and risk of other diseases related to adipose tissue distribution,
     such as diabetes, hypertension, gallbladder disease and polycystic
     ovaries.  This includes consideration of risk factors that may
     relate to cancer and to other diseases, such as serum lipids and
     variations in lipid metabolism.
     
  o  Evaluation of the etiologic validity of cancer risk estimates
     derived from case/control studies of adiposity or adipose tissue
     distribution.
     
  o  Improved definition of the relationship between steroid hormone
     metabolism and adiposity, including adipose tissue patterning, as
     this information contributes to knowledge of cancer risk.  This
     includes improved understanding of the role and causes of variation
     in hormone binding, both to hormone binding globulins and to
     cellular receptors in humans.
     
  o  Insight into whether environmental factors, which influence both
     cancer risk and steroid hormone metabolism, act directly as well as
     indirectly in affecting cancer risk.  Environmental factors of
     interest include smoking, dietary variation, energy balance, and
     intake of specific substances such as indoles, ethyl alcohol,
     saturated and unsaturated fatty acids.
     
  o  Studies of the impact of fluctuations in body fat over time on the
     mobilization of substances stored in body fat (such as pesticides)
     and the relationship of such changes to cancer etiology.
     
              NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 9
  o  Determination of the relationship to cancer risk of site-specific
     variation in adipose tissue activity.
     
  o  Investigation into reasons for the cross-over in obesity-associated
     risk of breast cancer in pre- and post-menopausal women.
     
  o  Determination of whether adiposity/fat patterning, examined across
     age without regard to menopausal status, distinguishes populations
     with differing constellations of risk factors, as is true of the
     pre- and post-menopausal risk factor patterns.
     
  o  Evaluation of important health/physiologic effects associated with
     modification of major cancer risk factors, such as altering the
     quantity or quality of circulating estrogenic or androgenic
     hormones, weight reduction, and/or dietary intervention.
     
Where feasible and appropriate, applications for the proposed epidemiologic
studies should include a suitable representation of minorities and women.  If
the applicant cannot comply, a clear rationale for their exclusion must be
provided.
     
IV.  MECHANISM OF SUPPORT
     
This program will be supported through traditional research (R01) grants.
Awards will be administered under Public Health Service grants policy as
stated in the PHS Grants Policy Statement, DHHS Publication No. (OASH)
82-50,000, revised January 1, 1987.  The total project period for applications
submitted in response to this Program Announcement should not exceed five
years.  This topic is expected to be of long-term interest and will remain in
effect until retracted.  Grantees interested in submitting renewal
applications should inquire if it remains in effect; if not, an unsolicited
application may be submitted in the usual way.
     
V. ELIGIBILITY
     
Non-profit and for-profit organizations and institutions, governments and
their agencies, and individuals are eligible to apply.  Foreign and domestic
institutions are eligible.
     
VI.  APPLICATION AND REVIEW PROCEDURES
     
Applications must be submitted on FORM PHS-398, revised 10/88, available in
the business or grants office at most academic or research institutions, or
from the Division of Research Grants, National Institutes of Health, Room 449,
Westwood Building, 5333 Westbard Avenue, Bethesda, Maryland 20892.  The format
and instructions applicable to regular research grant applications should be
followed.  Deadline dates for submission of applications for R01 applications
are on or before February 1, June 1, or October 1, annually.
     
The phrase "IN RESPONSE TO PROGRAM ANNOUNCEMENT -- PA-90-12 OBESITY AND CANCER
RISK" must be typed on line 2 of the face page of the application, and YES
must be checked.  The completed, signed original and six (6) signed, exact
copies should be submitted in one package to the Division of Research Grants
at the address below.  The photocopies must be clear and single-sided.
     
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
5333 Westbard Avenue
Bethesda, MD  20892**
     
The Division of Research Grants will not accept any application in response to
this announcement that is the same as one currently being considered by any
other National Institutes of Health awarding unit.  Applications will be
assigned to the most appropriate regular study section by the Division of
Research Grants.  The second level of review will be performed by an
appropriate national advisory council or board.  Funding decisions will be
based on the above evaluations and on the availability of funds.
     
Review criteria considered in evaluating applications include:
     
  o  Scientific merit and originality of research approach, design, and
     methodology;
     
  o  Research experience and competence of the Principal Investigator
     and staff to conduct the proposed studies;
     
  o  Documentation of appropriate collaborative arrangements;
     
             NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 10
  o  Adequacy of time (effort) that the Principal Investigator and staff
     would devote to the proposed studies;
     
  o  Adequacy of essential facilities and resources, or completeness and
     feasibility of the plans for their establishment.
     
The review group will recommend an appropriate budget for each approved
application.
     
VII.  INQUIRIES
     
Inquiries concerning this announcement should be directed to:
     
Genrose Copley, M.D.
Extramural Programs Branch
Epidemiology and Biostatistics Program
Division of Cancer Etiology
National Cancer Institute
Executive Plaza North, Suite 535
Bethesda, MD  20892
Telephone:  (301) 496-9600
     
This program is described in the Catalog of Federal Domestic Assistance No.
13.393, Cancer Cause and Prevention Research.  Awards will be made under
authorization of the Public Health Service Act, Title III, Section 301(c) and
Section 402 (Public Law 78-410, as amended; 42 USC 241; 42 USC 282) and
administered under PHS grant policies and Federal regulations 42 CFR Part 52
and 45 CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency review.

MINORITY INSTITUTIONAL RESEARCH TRAINING PROGRAM
     
PA:  PA-90-13
     
P.T. 42, FF; K.W. 0720005, 0715040, 0715165, 0785070
     
National Heart, Lung, and Blood Institute
     
Application Receipt Date:  August 22, 1990
     
The National Heart, Lung, and Blood Institute (NHLBI) announces a program to
support full-time research training for investigative careers at minority
schools in areas related to cardiovascular, pulmonary or hematologic diseases.
Minority schools seeking this support must have:  (1) graduate students or (2)
health professional students who will take a minimum of one year from his/her
professional training or (3) postdoctoral students.  The support mechanism
will be the NIH institutional research training grant.  Copies of the program
guidelines are currently available from staff of the NHLBI listed below.
     
Grants in this program will be made to minority institutions, each of which
will cooperate with a research center that has a well-established
cardiovascular, pulmonary or hematologic research and research training
program.  Each trainee will be placed with a mentor who is an accomplished
investigator at the cooperating research center and who will assist the
advisor at the minority institution in the trainee's development and research
plan.
     
Guidelines for this program may be obtained from any of the following:
     
John Fakunding, Ph.D.
Chief, Research Training and Development Branch
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 3C04
Bethesda, MD  20892
Telephone:  (301) 496-1724
     
Diane Aiken
Division of Lung Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Westwood Building, Room 640A
Bethesda, MD  20892
Telephone:  (301) 496-7668

     
             NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 11
Helena Mishoe, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 504d
Bethesda, MD  20892
Telephone:  (301) 496-6931
     
This program is described in the Catalog of Federal Domestic Assistance number
13.837, 13.838, and 13.839.  Award will be made under the authority of the
Public Health Service Act, Title III, Section 301 (Public Law 78-410, as
amended; 42 USC 241) and administered under PHS grant policies and Federal
Regulations at 42 CFR Part 52 and 45 CFR Part 74.  This program is not subject
to the intergovernmental review requirements of Executive Order 12372 or
Health Systems Agency review.

MINORITY SCHOOL FACULTY DEVELOPMENT AWARD
     
PA:  PA-90-14
     
P.T. 34, FF; K.W. 0720005, 0715040, 0715165, 0785070
     
National Heart, Lung, and Blood Institute
     
Application Receipt Date:  August 22, 1990
     
The National Heart, Lung, and Blood Institute (NHLBI) announces a program to
encourage the development of faculty investigators at minority schools in
areas relevant to cardiovascular, pulmonary and hematologic diseases and
resources.  Copies of the program guidelines are currently available from the
staff of the NHLBI, listed below.
     
Grants in this program will be made to minority institutions on behalf of
awardees, each of whom will work with a mentor at a nearby (within 100 miles)
research center, who is recognized as an accomplished investigator in the
research area proposed and who will provide guidance for the awardee's
development and research plan.
     
Guidelines for this program may be obtained from any of the following:
     
John Fakunding, Ph.D.
Chief, Research Training and Development Branch
Division of Heart and Vascular Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 3C04
Bethesda, MD  20892
Telephone:  (301) 496-1724
     
Joan  M. Wolle, Ph.D., M.P.H.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
National Institutes of Health
Westwood Building, Room 640
Bethesda, MD  20892
Telephone:  (301)  496-7668
     
Helena Mishoe, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 504d
Bethesda, MD  20892
Telephone (301) 496-6931
     
This program is described in the Catalog of Domestic Assistance Nos. 13.837,
13.838, and 13.839.  Awards will be made under the authority of the Public
Health Service Act, Title III, Section 301 (Public Law 78-410 as amended; 42
USC 241) and administered under PHS grant policies and Federal Regulation 42
CFR Part 52 and 45 CFR Part 74.  This program is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review.

     

     
             NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 12
                                   ERRATUM

ACADEMIC AWARD IN SYSTEMIC AND PULMONARY VASCULAR DISEASE
     
P.T. 34; K.W. 0715165, 0785035
     
National Heart, Lung, and Blood Institute
     
Application Receipt Date:  October 22, 1990
     
PURPOSE
     
The following is a correction notice to reflect a change in the Program
Announcement entitled, "Academic Award in Systemic and Pulmonary Vascular
Disease," published in the NIH Guide for Grants and Contracts in Volume 19,
No. 5, on February 2, 1990.  The change relates to the minimum percent effort
required by the Awardee.
     
The effective implementation of this Academic Award will require the support
of individuals who have significant current research in some facet of vascular
medicine, who have academic appointments which will allow a meaningful
influence on the coordination of vascular disease within their institution,
and who can provide clinical consultation and primary care, and leadership and
guidance in education and research.  Awardees are encouraged to devote 50
percent effort to developing, improving and implementing a vascular disease
program.  However, some individuals with these credentials may not be able to
commit 50 percent effort as is currently required by the Guidelines.  The
National Heart, Lung, and Blood Institute, therefore, announces a decrease in
the minimum percent effort required of the Awardee.  Based on adequate
justification, which should include significant time commitment to research
activities in the area of vascular disease, prospective awardees may propose
to commit less than 50 percent of their time to this Award.  In no case will
applications proposing less than 25 percent effort be considered responsive to
this announcement.
     
The initial review process will consider the appropriateness of the proposed
Awardee's percent effort in light of other proposed staff with support and
coordinating responsibilities in the program.  A description of significant
research activities in the area of vascular disease must also be provided.
     
Program guidelines are available from staff of the National Heart, Lung, and
Blood Institute as detailed in the NIH guide for Grants and Contracts, Vol.
19, No. 5, on February 2, 1990.

THE STUDY OF THE ETIOLOGY AND PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE
     
PA: PA-90-05
     
P.T. 34; K.W. 0715085, 0765033, 0755030, 1002019, 0710070
     
National Institute of Diabetes and Digestive and Kidney Diseases and the
National Institute of Allergy and Infectious Diseases
     
This program announcement was published in the NIH Guide for Grants and
Contracts on April 27, 1990, Vol. 19, No. 17.  That announcement omitted the
National Institute of Allergy and Infectious Diseases as a co-sponsor of this
program announcement.

**THE MAILING ADDRESS GIVEN FOR SENDING APPLICATIONS TO THE DIVISION OF
RESEARCH GRANTS OR CONTACTING PROGRAM STAFF IN THE WESTWOOD BUILDING IS THE
CENTRAL MAILING ADDRESS FOR THE NATIONAL INSTITUTES OF HEALTH.  APPLICANTS WHO
USE EXPRESS MAIL OR A COURIER SERVICE ARE ADVISED TO FOLLOW THE CARRIER'S
REQUIREMENTS FOR SHOWING A STREET ADDRESS.  THE ADDRESS FOR THE WESTWOOD
BUILDING IS:
     
5333 Westbard Avenue
Bethesda, Maryland 20816

     

     

     
             NIH GUIDE - Vol. 19, No. 19, May 18, 1990 - Page 13